Verastem - Turnaroundspekulation 2016

Verastem Oncology Signs Definitive Agreement to Sell COPIKTRA® (duvelisib) Rights to Secura Bio to Focus on Development of VS-6766 and Defactinib in KRAS Mutant Solid Tumors

https://finance.yahoo.com/news/...c9&_guc_consent_skip=1597065811

Verastem Oncology Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress

https://finance.yahoo.com/news/...c9&_guc_consent_skip=1597065843  

 

Allen ein schönes WE!  

Schade, hab die Kurse unter 1.10$ verpasst, aber einen Alarm gesetzt falls es nochmal runter gehen sollte.

https://www.fool.com/investing/2020/08/10/...riefly-this-morning.aspx

 

Dann solltest du heute noch einsteigen.


Verastem Oncology Announces Investor Conference Call to Discuss Updated Clinical Data in Low-Grade Serous Ovarian Cancer from Phase 1/2 FRAME Study


-New Results Evaluating Combination of VS-6766 and Defactinib to be Presented at the 2nd Annual RAS-Targeted Drug Development Summit

-Management to Host Investor Conference Call and Webcast on Wednesday, September 16 at 8:00 AM ET


https://finance.yahoo.com/news/...-investor-conference-110000045.html  

Verastem Oncology Announces Presentation of Updated Phase 1/2 FRAME Study Data at the 2nd Annual RAS-Targeted Drug Development Summit


-Preliminary Data on VS-6766 and Defactinib Combination Continues to Show Encouraging Response Rates, Durability and a Favorable Safety Profile in KRAS Mutant Low-Grade Serous Ovarian Cancer in Investigator-Initiated Trial

-New Preclinical Data Demonstrating Synergy and Tumor Regression with G12C Inhibitors in Combination with VS-6766 and FAK Inhibitor In Vitro and In Vivo Also Presented


https://finance.yahoo.com/news/...presentation-updated-110000934.html  

https://old.nasdaq.com/de/symbol/vstm/real-time
 

http://ih.advfn.com/...p;width=800&vol=1&height=400&Vol=1  

VS-6766 Daten

https://investor.verastem.com/news-releases/...lished-lancet-oncology

 

Zurück auf Los.  

Zahlen für Q3/20

• Umsatz 79 Mio. $
  
  • 70 Mio. $ aus dem  COPIKTRA Verkauf
    
• Gewinn 13 Mio. $
  
• Cash 206 Mio. $
  
• MK 244 Mio. $
  

"Strategic Sale of COPIKTRA® (duvelisib) Provides Cash Runway Until at Least 2024"

https://investor.verastem.com/news-releases/...2020-financial-results

 

http://ih.advfn.com/...p;width=800&vol=1&height=400&Vol=1  

https://www.marketwatch.com/investing/stock/vstm  

https://www.marketwatch.com/investing/stock/vstm  

Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Previous Data from Investigator-Initiated Phase 1/2 Trial Show Encouraging Response Rates, Durability and a Favorable Safety Profile

Phase 2 Adaptive Trial Design to Evaluate VS-6766 Alone and in Combination with Defactinib

Verastem to Seek FDA Accelerated Approval, Pending Trial Outcome

https://investor.verastem.com/news-releases/...tration-directed-trial  

BARBERICH TIMOTHY J
Shares: 50.000
Price: $2.17
Amount: $108,500
File date: 07.12.20

http://insiderbuyingselling.com/?t=VSTM  

Annual Changes to the Nasdaq Biotechnology Index

https://www.nasdaq.com/press-release/...omltfnd5Ydzg9ZvR-2rtzaHfdb16k  

jetzt sind wir leider schon gut  10% im Minus vom letzten Hoch , schade. Sah richtig gut , immer stetig nach oben. Meine ihr , es geht jetzt noch weiter runter !  

Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Previously Treated KRAS Mutant Non-Small Cell Lung Cancer

Phase 2 Adaptive Trial Design to Evaluate VS-6766 Alone and in Combination with Defactinib With a Focus on KRAS-G12V Mutations

Trial Designed to Address Significant Unmet Medical Need in These Treatment-Resistant Tumors

Verastem Oncology to Seek FDA Accelerated Approval, Pending Trial Outcome

https://finance.yahoo.com/news/...gy-initiates-phase-2-120000499.html  

Premarket mit verdammt niedrigen Volumen.  

 

 

 

 

CMO geht nach nur 2 Wochen

Das wirft natürlich Fragen auf...

https://www.fiercebiotech.com/biotech/...weeks-into-job-its-cmo-quits